Double-Nucleoside Therapy for HIV in Pregnant Women
Author Information
Author(s): NS Silverman MD, MM DiVito RN, MSN, D Robbins MSN, CRNP
Primary Institution: Division of MFM, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA
Hypothesis
The study aims to evaluate the safety profiles of double-nucleoside therapy for HIV-infected pregnant women and their newborns.
Conclusion
Double-nucleoside therapy in HIV-infected pregnant women shows comparable safety profiles to AZT alone, with high acceptance and tolerance.
Supporting Evidence
- All patients delivered at term with no significant changes in hematologic or liver function values.
- None of the patients stopped therapy for side effects.
- 4 out of 9 newborns had mild anemia, but none required blood transfusions.
- Elevated transaminases were seen in 7 out of 9 newborns, but none required therapy.
Takeaway
This study looked at how safe it is to use two HIV medications together in pregnant women, and found it to be safe for both moms and babies.
Methodology
The study involved offering therapy with AZT and a second nucleoside agent to HIV-infected pregnant women, monitoring their health and that of their newborns.
Limitations
The study is limited by its small sample size and preliminary nature.
Participant Demographics
The study included HIV-infected pregnant women receiving treatment at a medical institution.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website